Volume 26, Number 3—March 2020
Research
Human Immune Responses to Melioidosis and Cross-Reactivity to Low-Virulence Burkholderia Species, Thailand1
Patpong Rongkard, Barbara Kronsteiner, Viriya Hantrakun, Kemajittra Jenjaroen, Manutsanun Sumonwiriya, Panjaporn Chaichana, Suchintana Chumseng, Narisara Chantratita, Vanaporn Wuthiekanun, Helen A. Fletcher, Prapit Teparrukkul, Direk Limmathurotsakul, Nicholas P.J. Day, and Susanna J. Dunachie
Table 2
Characteristics of patients and controls in study of immune responses to melioidosis and cross-reactivity to low-virulence Burkholderia species, by cohort, Thailand*
| Baseline characteristics | Cohort |
|||
|---|---|---|---|---|
| Melioidosis, n = 99 | Healthy controls, n = 96 | Diabetes controls, n = 98* | Other gram-negative bacterial infections, n = 48 | |
| Sex | ||||
| M | 63 (64) | 27 (28) | 25 (26) | 27 (56) |
| F |
36 (36) |
69 (72) |
73 (74) |
21 (44) |
| Age, y, median (range) |
55 (20–84) |
48 (25–69) |
53 (41–60) |
64 (24–95) |
| Diabetes† |
66 (67) |
NA |
98 (100) |
NA |
| Died‡ | 30 (30) | NA | NA | NA |
| Survived | 69 (70) | NA | NA | NA |
*Values are no. (%) except as indicated.
†Includes patients who were previously diagnosed with diabetes or who have a hemoglobin A1C level >6.5% at time of recruitment.
‡Died within 28 days of study enrollment.
1Preliminary results from this study were presented at the European Melioidosis Congress, March 19–21, 2018, Oxford, UK.
Page created: February 19, 2020
Page updated: February 19, 2020
Page reviewed: February 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.